Santen Pharmaceutical (OTCMKTS:SNPHY) Stock Price Down 8.5% – Here’s Why

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY)’s share price dropped 8.5% during mid-day trading on Friday . The company traded as low as $11.59 and last traded at $11.59. Approximately 455 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 11,254 shares. The stock had previously closed at $12.67.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One research analyst has rated the stock with a Hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Santen Pharmaceutical Price Performance

The firm has a market capitalization of $3.89 billion and a P/E ratio of 0.10. The firm’s fifty day moving average price is $12.48 and its 200-day moving average price is $11.52.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.